Asian Spectator


The Times

.

CPA Australia outlines recommendations for Hong Kong’s First Five-Year Plan and 2026 Policy Address

HONG KONG SAR – Media OutReach Newswire – 13 August 2026 – CPA Australia has suggested the HKSAR Government to use Hong Kong's First Five-Year Plan (2026–2030) and the 2026 ...

Really Simple Systems Launches Zapier Template for QuickBooks ...

PETERSFIELD, England, September 12, 2019, /PRNewswire-AsiaNet/-- Leading cloud CRM vendor, Really Simple Systems, is pleased to announce the launch of a new integration with accounting softw...

Traveloka has joined as a Member of the Global Sustainable Tourism Council

This membership underlines Traveloka’s commitment in realizing sustainable tourismSINGAPORE - Media OutReach - 14 June 2022 - Traveloka, Southeast Asia's lifestyle superapp, today an...

Artmarket.com fosters art market transparency via Artprice sub...

PARIS, Feb. 9, 2021 /PRNewswire-AsiaNet/ -- Somewhat counter-intuitively, the dematerialization of auctions has not greatly improved the transparency of the secondary art market. For sure, ...

Ascend receives quality award from General Motors

HOUSTON, July 1, 2021 /PRNewswire-AsiaNet/ -- Ascend Performance Materials has received the General Motors 2020 Supplier Quality Excellence Award for its Pensacola, Florida, polyamide 66 pla...

RedHill Biopharma Further Expands Opaganib Manufacturing Capac...

TEL AVIV, Israel and RALEIGH, N.C., Jan 28 2021 /PRNewswire-AsiaNet/ -- New agreement further expands manufacturing capacity for orally-administered opaganib following positive top-line data...

Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 ...

MANASSAS, Va., Nov. 10, 2021 /PRNewswire-AsiaNet/ -- Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testi...

Eka Global: Supply Remains Priority for Food Packaging During ...

BANGKOK, Apr. 20, 2020 /PRNewswire-AsiaNet/-- Despite some challenges from coronavirus outbreak, Eka Global, one of the world's leading longevity packaging producers, confirmed no compromise...

3 International Cancer Researchers to Receive the 2021 Fondati...

PARIS, April 20, 2021 /PRNewswire-AsiaNet/ -- Whilst the Fondation ARC Léopold Griffuel Prize is widely recognised today as one of the most prestigious European awards in the field of...

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

SYDNEY, Apr 8, 2020 - (ACN Newswire) - Asia-Pacific's largest specialist biotech CRO Novotech said the top 10 biotech sites in Australia were open for clinical trial activity with many sites modifying their practices to ensure continuity of operations.

Novotech Data Shows Majority of Australian Sites are Open for Clinical Trial Activity

View and Download the COVID-19 Australia Data Bulletin here. https://novotech-cro.com/covid-19-notice

The data is part of a new series prepared for Novotech clients detailing the current status of trials in the Asia-Pacific during the global COVID-19 crisis.

Novotech CEO Dr John Moller said the Bulletin series taps local knowledge of fundamentals in the sector and shows which countries in the region are able to support clinical research for Novotech and its clients during this time.

"While the situation is always evolving, Australia appears to be managing the crisis well. Our sites have changed how they manage trials in line with Australian Government health guidelines and most are still able to deliver the clinical trial services we need for our clients," said Dr Moller. "Study delays caused by COVID-19 can be rapidly addressed by activating new sites in Australia and Asia."

Australia has attractive start-up times, world leading investigators and research teams, and valuable rebates of up to 43.5% on clinical trial spend.

About Novotech

Novotech, established in 1996, is internationally recognized as the leading full-service contract research organization (CRO) in Asia-Pacific. Novotech provides clinical development services across all clinical trial phases and therapeutic areas and has been instrumental in the success of over a thousand Phase I - IV clinical trials for biotech companies.

Novotech obtained the ISO 27001, the best-known standard in the ISO family, providing the requirements for an Information Security Management System. Together with the ISO 9001 Quality Management system, Novotech aims at the highest IT security and quality standards for patients and biotechnology companies. Visit http://novotech-cro.com.

For RFP enquiries: Please fill out the form available at https://novotech-cro.com/talk-to-an-expert

Media ContactSusan Fitzpatrick-Napiercommunications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

Authors: ACN Newswire - Press Releases

Read more //?#

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-libraryjojobetjojobetgrandpashabetPadişahbetPadişahbetDizipalStreamEastPadişahbetGalabetjojobetjojobetcasibomhttps://chantilly-montessori-school.vercel.app/esim senegalbetparkbetparktelegram下载zlibrary bookscasino en lignejojobetjojobetholiganbet